Details for Patent: 11,253,523
✉ Email this page to a colleague
Which drugs does patent 11,253,523 protect, and when does it expire?
Patent 11,253,523 protects XELJANZ XR and is included in one NDA.
This patent has forty-eight patent family members in twenty-four countries.
Summary for Patent: 11,253,523
| Title: | Tofacitinib oral sustained release dosage forms |
| Abstract: | The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics. |
| Inventor(s): | Herbig; Scott Max (East Lyme, CT), Krishnaswami; Sriram (East Lyme, CT), Kushner, IV; Joseph (Bradford, RI), Lamba; Manisha (Waterford, CT), Stock; Thomas C. (Chester Springs, PA) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 16/817,689 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Delivery; Device; Dosage form; |
Drugs Protected by US Patent 11,253,523
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-001 | Feb 23, 2016 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | A METHOD OF TREATING ANKYLOSING SPONDYLITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, AND 87-98 | ⤷ Subscribe | ||||
| Pfizer | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-001 | Feb 23, 2016 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | A METHOD OF TREATING PSORIATIC ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, AND 87-98 | ⤷ Subscribe | ||||
| Pfizer | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-001 | Feb 23, 2016 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | A METHOD OF TREATING RHEUMATOID ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 AND 87-98 | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,253,523
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 095487 | ⤷ Subscribe | |||
| Australia | 2014233850 | ⤷ Subscribe | |||
| Australia | 2017203334 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
